Autosomal recessive otospondylomegaepiphyseal dysplasia

Autosomal recessive otospondylomegaepiphyseal dysplasia (OSMED), also known as Insley-Astley syndrome or Weissenbacher-Zweymüller syndrome (though the latter is sometimes considered a separate but overlapping condition), is a rare inherited skeletal disorder caused by mutations in the COL11A2 gene, which encodes the alpha-2 chain of type XI collagen. This condition primarily affects the skeletal system, the joints, and hearing. The name reflects its cardinal features: oto (ear/hearing), spondylo (spine), mega (large), epiphyseal (growth centers of bones), and dysplasia (abnormal development). Key clinical features include sensorineural hearing loss, which can be severe to profound, along with distinctive skeletal abnormalities such as enlarged epiphyses (the ends of long bones), platyspondyly (flattened vertebral bodies), and short limbs resulting in disproportionate short stature. Affected individuals often have characteristic facial features including midface hypoplasia (underdevelopment of the middle portion of the face), a depressed nasal bridge, and micrognathia (small jaw), which may be particularly prominent in infancy. Cleft palate may also be present. Joint problems, including early-onset osteoarthritis and limited joint mobility, can develop over time. There is currently no cure for autosomal recessive OSMED. Treatment is supportive and multidisciplinary, focusing on management of hearing loss with hearing aids or cochlear implants, orthopedic interventions for skeletal complications, and surgical correction of cleft palate if present. Regular monitoring by audiologists, orthopedic specialists, and other relevant healthcare providers is recommended. Early intervention for hearing loss is particularly important to support speech and language development in affected children.

Common questions about Autosomal recessive otospondylomegaepiphyseal dysplasia